查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2082138

1 型糖尿病治療市場：2026-2032 年全球市場預測，按胰島素類型、劑量形式、給藥途徑、治療階段、分銷管道、最終用戶和患者年齡層分類。

Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Route Of Administration, Treatment Line, Distribution Channel, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，1 型糖尿病藥物市場規模將成長至 390.7 億美元，複合年成長率為 9.32%。

主要市場統計數據
基準年 2025 209.3億美元
預計年份：2026年 227.5億美元
預測年份 2032 390.7億美元
複合年成長率 (%) 9.32%

1 型糖尿病治療市場的發展得益於臨床上對終身胰島素替代療法的日益重視、胰島素類似物的廣泛應用以及針對自體免疫BETA細胞破壞的疾病修正治療。實證流行病學數據也凸顯了商業性和公共衛生需求。根據美國疾病管制與預防中心（CDC）的數據顯示，美國約有200萬人患有第1型糖尿病，其中包括超過30萬名兒童和青少年。同時，《刺胳針》雜誌發表的一項全球調查估計，全世界有數百萬人患有這種疾病。

早期診斷、部分地區兒童發病率上升、持續血糖監測和自動胰島素輸注的普及，以及保險公司要求提供能夠緩解嚴重低血糖、糖尿病酮酸症和長期併發症的治療方案，都在影響著市場需求。此外，市場正從血糖控制轉向免疫干預，例如美國FDA核准teplizumab用於延緩8歲及以上合格的3期1型糖尿病患者的病情進展。

1型糖尿病藥物領域的變革性變化

1型糖尿病治療市場最顯著的變化是從單純的胰島素治療轉向涵蓋預防、延緩發作、精準給藥和減少併發症的持續治療方案。雖然速效和長效胰島素類似物仍然必不可少，但生物相似藥和仿製胰島素產品正在加劇關鍵市場的價格競爭，並提高保險覆蓋範圍的柔軟性。

人工智慧的累積影響

人工智慧（AI）正對第1型糖尿病疾病管理的各個領域產生累積影響，從藥物發現和臨床開發到實際臨床實踐。人工智慧模型正被用於分析免疫學生物標記、遺傳風險評分、電子健康記錄、臨床試驗資料集和血糖值數據，以識別疾病進展風險較高的患者，並支持更有效率地招募臨床試驗參與者。

主要市場的關鍵區域洞察

北美仍然是第1型糖尿病治療領域最先進的地區，其中美國處於領先地位。高診斷率、專業的內分泌網路、廣泛的持續血糖監測以及對先進糖尿病技術的保險報銷，都促進了高階胰島素類似物和免疫療法等創新方法的應用。在加拿大，儘管臨床指引的一致性和公共衛生支持力度都很強，但各省在保險報銷制度上的差異影響了患者獲得胰島素製劑、糖尿病醫療設備和支持性護理服務的機會。

策略市場擴張的關鍵集團洞察

歐盟是第1型糖尿病治療領域至關重要的政策和報銷中心。這是因為集中化的監管流程、不斷推進的衛生技術評估（HTA）改革、藥物警戒標準以及生物相似藥的引入，正在影響著各成員國的藥物定價和可及性。七國集團（G7）憑藉其強大的研發能力、高階療法的引進、在兒童糖尿病領域的專業知識以及嚴格的支付方審查，在胰島素類似物、免疫療法、BETA細胞保護和BETA細胞替代療法等方面的循證實踐中發揮著核心作用。

主要國家1型糖尿病藥物市場趨勢

美國是最大的商業市場，這得益於其高度重視治療、積極採用創新療法、開展活躍的臨床試驗以及在延緩疾病進展療法方面已有的監管先例。加拿大、英國、德國、法國、義大利和西班牙受益於完善的內分泌服務、兒童糖尿病網路和以指南為基礎的醫療保健體系，但報銷決策與成本效益證據、真實世界結果和預算影響密切相關。在俄羅斯和墨西哥，對胰島素的可近性和可負擔性有著持續的需求，公共採購、國內供應優先權和分銷可靠性發揮著至關重要的作用。

為行業領導者提供的實用建議

產業領導者應優先考慮那些除了HbA1c水平之外還能產生可衡量臨床價值的療法，包括延長血糖值維持在目標範圍內的時間、減少嚴重低血糖的發生、降低糖尿病酮酸症的發生率、維持BETA細胞功能、延緩疾病進展至症狀性階段以及提高生活品質。證據包應整合來自動態血糖監測儀（CGM）、胰島素幫浦、保險理賠數據、電子健康記錄和註冊登記的真實世界數據，以及隨機對照試驗的數據。

調查方法

本執行摘要基於二手檢驗，所用資訊來源可靠，包括公共衛生機構和監管資料庫、臨床試驗註冊庫、同行評審期刊、糖尿病協會指南以及公開的醫療保健政策文件。分析重點關注來自美國疾病管制與預防中心 (CDC)、世界衛生組織 (WHO)、美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、國際糖尿病聯盟 (IDF) 等機構以及權威臨床期刊的證據。

結論

1型糖尿病治療市場正進入一個新階段，疾病修正治療、數位整合和精準醫療正在建立差異化的策略路徑，而胰島素仍然是基礎。延緩疾病發作的免疫療法的獲批，展現了第1型糖尿病治療中更廣泛的預防和介入模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：第一型糖尿病治療市場：依胰島素類型分類

  • 中間型
  • 長效型
  • 快速起效
  • 短效

第8章：第1型糖尿病治療藥物市場：依劑型分類

  • 筆
  • 泵浦
  • 注射器

第9章：第1型糖尿病治療市場：依給藥途徑分類

  • 皮下
  • 靜脈

第10章：第1型糖尿病藥物市場：依治療階段分類

  • 一線治療
  • 第二行
  • 從第三行開始

第11章：第1型糖尿病藥物市場：依分銷管道分類

  • 離線
  • 線上

第12章：第1型糖尿病治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第13章：第一型糖尿病藥物市場：依患者年齡層別分類

  • 成人
  • 老年人
  • 兒童

第14章：第一型糖尿病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：第一型糖尿病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：第一型糖尿病藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Adocia
  • Arecor Therapeutics PLC
  • AstraZeneca PLC
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Civica, Inc.
  • Diasome Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Lexicon Pharmaceuticals Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Provention Bio Inc.
  • Sandoz Group AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zealand Pharma A/S
Product Code: MRR-43676CF429EB

The Type 1 Diabetes Drug Market is projected to grow by USD 39.07 billion at a CAGR of 9.32% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.93 billion
Estimated Year [2026] USD 22.75 billion
Forecast Year [2032] USD 39.07 billion
CAGR (%) 9.32%

The type 1 diabetes drug market is anchored by lifelong insulin replacement, expanding use of insulin analogs, and a rising clinical focus on disease-modifying therapies that address autoimmune beta-cell destruction. Verified epidemiology underscores the commercial and public health need: CDC data show that about 2 million people in the United States live with type 1 diabetes, including more than 300,000 children and adolescents, while global research published in The Lancet estimates millions of people worldwide are affected.

Demand is shaped by earlier diagnosis, pediatric incidence growth in several regions, broader access to continuous glucose monitoring and automated insulin delivery, and payer pressure for therapies that reduce severe hypoglycemia, diabetic ketoacidosis, and long-term complications. The market is also moving beyond glycemic control toward immune intervention, exemplified by U.S. FDA approval of teplizumab to delay stage 3 type 1 diabetes in eligible patients aged 8 years and older.

Transformative Shifts in the Type 1 Diabetes Drug Landscape

The most important shift in the type 1 diabetes drug landscape is the transition from insulin-only management toward a continuum that includes prevention, delay, precision dosing, and complication reduction. Rapid-acting and long-acting insulin analogs remain essential, while biosimilar and follow-on insulin products are increasing price competition and improving formulary flexibility in major markets.

At the same time, immune-modifying drugs, beta-cell preservation strategies, stem-cell-derived islet replacement, and encapsulation technologies are reshaping R&D priorities. Regulatory agencies are increasingly open to clinically meaningful endpoints such as delaying disease onset, reducing insulin dependency, preserving C-peptide, and improving time in range, which is shifting investment toward therapies that can change the natural history of type 1 diabetes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across type 1 diabetes drug discovery, clinical development, and real-world disease management. AI models are used to analyze immunologic biomarkers, genetic risk scores, electronic health records, clinical trial datasets, and glucose data to identify patients at risk of progression and support more efficient trial recruitment.

In commercial care pathways, AI-enabled insulin decision support and automated insulin delivery algorithms can improve glucose control when integrated with CGM and pump ecosystems. For drug developers, AI strengthens pharmacovigilance, adherence analytics, and comparative effectiveness research, helping demonstrate outcomes that payers increasingly require for reimbursement and long-term access.

Key Regional Insights Across Major Markets

North America remains the most advanced region for type 1 diabetes drugs, led by the United States, where high diagnosis rates, specialty endocrinology networks, continuous glucose monitoring adoption, and reimbursement for advanced diabetes technologies support uptake of premium insulin analogs and immune-therapy innovation. Canada shows strong clinical guideline alignment and public health support, although provincial reimbursement variation influences access to insulin formulations, diabetes devices, and adjunct care services.

Europe benefits from structured diabetes registries, national health systems, pediatric diabetes programs, and broad use of biosimilar insulin in cost-containment strategies. Asia-Pacific is expanding its clinical relevance as China, India, Japan, Australia, and South Korea improve screening, pediatric endocrinology capacity, reimbursement pathways, and digital diabetes management. Latin America demonstrates rising need as Brazil and Mexico expand public-sector diabetes care, though affordability and procurement consistency remain important constraints. The Middle East, particularly high-income Gulf health systems, is investing in specialty diabetes centers, digital health, and prevention programs, while Africa faces the greatest access barriers due to insulin affordability, cold-chain requirements, trained specialist shortages, and inconsistent supply across many countries.

Key Group Insights for Strategic Market Expansion

The European Union is a critical policy and reimbursement bloc for type 1 diabetes drugs because centralized regulatory pathways, evolving health technology assessment reforms, pharmacovigilance standards, and biosimilar adoption influence pricing and access across member states. The G7 concentrates advanced R&D capacity, premium treatment adoption, pediatric diabetes expertise, and payer scrutiny, making it central to evidence generation for insulin analogs, immunotherapies, beta-cell preservation, and beta-cell replacement programs.

BRICS countries represent high-volume long-term treatment expansion potential, particularly through China, India, and Brazil, where expanding healthcare coverage, domestic biologics capacity, and improving diagnosis can increase treated populations, although affordability remains a defining access issue. ASEAN markets are improving diabetes infrastructure and digital health adoption but remain price sensitive, requiring scalable insulin access models and clinician education. GCC countries are investing in specialty care, chronic disease management, and connected diabetes technologies, supporting higher adoption of advanced therapies when evidence is compelling. NATO overlap with North America and Europe reinforces high standards for supply chain resilience, regulatory quality, biologics manufacturing security, and continuity of essential insulin supply.

Key Country Insights in the Type 1 Diabetes Drug Market

The United States is the leading commercial market due to high treatment intensity, innovation adoption, strong clinical trial activity, and regulatory precedent for disease-delaying therapy. Canada, the United Kingdom, Germany, France, Italy, and Spain benefit from established endocrinology services, pediatric diabetes networks, and guideline-driven care, though reimbursement decisions are closely tied to cost-effectiveness evidence, real-world outcomes, and budget impact. Russia and Mexico present sustained demand for insulin access and affordability, with public procurement, domestic supply priorities, and distribution reliability playing significant roles.

China and India offer major long-term opportunity as diagnosis improves, healthcare investment grows, and specialist networks expand, but affordability, awareness, rural access, and availability of advanced diabetes technologies remain barriers. Japan, Australia, and South Korea show strong adoption of advanced diabetes technologies, favorable clinical infrastructure, and high standards for post-market safety monitoring. Brazil is the most important Latin American country in this set, driven by public-sector insulin access, private healthcare growth, diabetes advocacy, and increasing attention to pediatric and adolescent type 1 diabetes care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that generate measurable clinical value beyond HbA1c, including improved time in range, lower severe hypoglycemia, reduced diabetic ketoacidosis, preserved beta-cell function, delayed progression to symptomatic disease, and better quality of life. Evidence packages should integrate randomized controlled trials with real-world data from CGM, pump, claims, electronic health record, and registry sources.

Organizations should also strengthen access strategies through tiered pricing, biosimilar partnerships, patient support programs, clinician education, and cold-chain reliability in emerging markets. For innovation portfolios, the highest-value opportunities include immune modulation, beta-cell replacement, precision insulin delivery, and AI-enabled adherence and risk stratification tools that align drug benefits with payer-relevant outcomes and practical care delivery.

Research Methodology

This executive summary is based on secondary research using verified sources such as public health agencies, regulatory databases, clinical trial registries, peer-reviewed journals, diabetes association guidance, and publicly available healthcare policy documents. The analysis prioritizes evidence from organizations including the CDC, WHO, U.S. FDA, EMA, International Diabetes Federation, and leading clinical publications.

Market interpretation applies cross-validation across epidemiology, treatment guidelines, reimbursement trends, product approvals, pipeline activity, clinical endpoints, digital diabetes adoption, and regional access conditions. Insights are structured to support strategic planning for type 1 diabetes drug developers, insulin manufacturers, biosimilar entrants, medtech partners, payers, and healthcare investors without relying on market sizing, market share, or forecasting assumptions.

Conclusion

The type 1 diabetes drug market is entering a new phase in which insulin remains foundational while disease modification, digital integration, and precision care create differentiated strategic pathways. The approval of immune therapy to delay disease onset has validated a broader preventive and interventional model for type 1 diabetes treatment.

Future leadership will depend on demonstrating durable clinical outcomes, expanding equitable access, ensuring reliable insulin supply, and combining drug innovation with data-driven care delivery. Organizations that align biologic innovation, AI-enabled evidence generation, and region-specific reimbursement strategies will be best positioned in this evolving market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Type 1 Diabetes Drug Market, by Insulin Type

  • 7.1. Intermediate-Acting
  • 7.2. Long-Acting
  • 7.3. Rapid-Acting
  • 7.4. Short-Acting

8. Type 1 Diabetes Drug Market, by Delivery Mode

  • 8.1. Pen
  • 8.2. Pump
  • 8.3. Syringe

9. Type 1 Diabetes Drug Market, by Route Of Administration

  • 9.1. Subcutaneous
  • 9.2. Intravenous

10. Type 1 Diabetes Drug Market, by Treatment Line

  • 10.1. First-Line
  • 10.2. Second-Line
  • 10.3. Third-Line And Beyond

11. Type 1 Diabetes Drug Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Type 1 Diabetes Drug Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Type 1 Diabetes Drug Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Type 1 Diabetes Drug Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Type 1 Diabetes Drug Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Type 1 Diabetes Drug Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Adocia
  • 18.2. Arecor Therapeutics PLC
  • 18.3. AstraZeneca PLC
  • 18.4. Biocon Limited
  • 18.5. Bristol-Myers Squibb Company
  • 18.6. Civica, Inc.
  • 18.7. Diasome Pharmaceuticals Inc.
  • 18.8. Eli Lilly and Company
  • 18.9. Gan & Lee Pharmaceuticals Co., Ltd.
  • 18.10. GlaxoSmithKline PLC
  • 18.11. Johnson & Johnson Services Inc.
  • 18.12. Lexicon Pharmaceuticals Inc.
  • 18.13. Lupin Limited
  • 18.14. MannKind Corporation
  • 18.15. Merck & Co. Inc.
  • 18.16. Mylan N.V.
  • 18.17. Novartis AG
  • 18.18. Novo Nordisk A/S
  • 18.19. Pfizer Inc.
  • 18.20. Provention Bio Inc.
  • 18.21. Sandoz Group AG
  • 18.22. Sanofi S.A.
  • 18.23. Sun Pharmaceutical Industries Ltd.
  • 18.24. Teva Pharmaceutical Industries Ltd.
  • 18.25. Viatris Inc.
  • 18.26. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LONG-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LONG-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LONG-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RAPID-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RAPID-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RAPID-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SHORT-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHORT-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SHORT-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PUMP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PUMP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PUMP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GCC TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. G7 TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. NATO TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 195. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 235. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)